Delivery Order 1232SC18D0002-12234919F0009

Genscript USA Incorporated will provide gene synthesis services to the National Institutes of Health's National Institute of Allergy and Infectious Diseases under a $12,500 firm fixed price purchase order. The one-year contract was awarded on September 14, 2023 and runs through September 13, 2024. Genscript will deliver the gene synthesis work from its location in Piscataway, New Jersey. No subcontractors or additional context were provided regarding the specific research being supported under...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $702,500 firm-fixed-price contract to Genscript USA Inc. to provide gene synthesis services in support of COVID-19 testing. Under the contract, Genscript will synthesize 150 genes and conduct 150 mutagenesis and 250 express cloning projects, as well as prepare 425 plasmids. These products and services will support the testing of COVID-19 antibody therapeutics, convalescent plasma, and vaccines...

This federal contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (HHS/CDC) to Genscript USA Inc., a for-profit biotechnology company, provides gene synthesis services. The $245,750.00 firm-fixed-price purchase order has a completion date of September 29, 2021 and was awarded on August 18, 2020. The contract does not have a set-aside designation. Genscript is a provider of gene synthesis, gene editing, custom protein and antibody...

Genscript USA Incorporated will provide gene synthesis and vector ark cloning services to the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). Under the terms of a $12,108 firm fixed price purchase order, Genscript will deliver the requested products and services between September 2023 and September 2024. As the prime contractor, Genscript will leverage its expertise...

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $37,889.60 firm fixed-price purchase order contract to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey, for custom gene synthesis and expression services. This requirement was sole-sourced to Genscript due to their specialized expertise in producing the specific gene constructs needed to support NIAID's vaccine research and development efforts. The contract...

This is a $8,073.05 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the synthesis of a specific gene, HHSN272201200153P. Genscript, which is not a small business set-aside, has received numerous previous contracts from HHS agencies like the National Institutes of Health, Centers for...

This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company, for custom gene synthesis services. The contract has a potential value of $21,275.80 and a completion date of August 19, 2020. Genscript, based in Piscataway, New Jersey, specializes in gene synthesis, gene editing, custom protein and...

The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases Division of Acquisitions awarded a purchase order contract valued at approximately $6,200 to Bio Basic Canada Inc. for gene synthesis services. Under contract number NIH102-1, Bio Basic will provide 15,292 units of gene synthesis at $0.39 per unit to the NIH NIAID DEA OA located in Bethesda, Maryland. The contract period of performance spans from December 9, 2009...

This is a $3,078,000.00 firm fixed-price contract awarded by the National Cancer Institute (NCI) to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of gene synthesis, peptide synthesis, and quality control analysis services to support the NCI Surgery Branch's clinical research efforts on mutation-reactive T-cells for the treatment of metastatic cancers. The contract has a 12-month base period with two 12-month option periods. There...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $17,709 purchase order to Genscript USA Inc. to provide custom gene synthesis and expression services in support of its research efforts. The firm fixed price contract has a period of performance from September 18, 2023 through December 31, 2023 and will be carried out by Genscript at its facility located in Bethesda, Maryland. No major subcontractors or set aside designations were identified....